[
    [
        {
            "time": "2021-01-14",
            "original_text": "资金弃高就低，科创板50指数大涨，抱团主线是否暂告一段落？",
            "features": {
                "keywords": [
                    "资金流向",
                    "科创板50",
                    "指数大涨",
                    "抱团主线"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "资金弃高就低，科创板50指数大涨，抱团主线是否暂告一段落？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "复星医药(600196.SH)子公司就针对人体TROP2靶点抗体产品签署许可协议",
            "features": {
                "keywords": [
                    "复星医药",
                    "TROP2靶点",
                    "抗体产品",
                    "许可协议"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)子公司就针对人体TROP2靶点抗体产品签署许可协议",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "复星医药：控股子公司复宏汉霖获ChioMe独占许可",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "ChioMe",
                    "独占许可"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：控股子公司复宏汉霖获ChioMe独占许可",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "人民金融·创新药指数涨0.28% | 国内首款CAR-T要来了，4款获突破性治疗认证，中国CAR-T疗法将迎突破",
            "features": {
                "keywords": [
                    "创新药指数",
                    "CAR-T",
                    "突破性治疗认证"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨0.28% | 国内首款CAR-T要来了，4款获突破性治疗认证，中国CAR-T疗法将迎突破",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "扬子江大丰收！13个新品搅局350亿市场，仿制药申报NO.1，46个过评品种霸屏",
            "features": {
                "keywords": [
                    "扬子江",
                    "新品",
                    "仿制药",
                    "过评品种"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "扬子江大丰收！13个新品搅局350亿市场，仿制药申报NO.1，46个过评品种霸屏",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "中国停止生产销售使用酚酞片，可能会诱发癌症！涉及多家上市公司",
            "features": {
                "keywords": [
                    "酚酞片",
                    "癌症风险",
                    "上市公司"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中国停止生产销售使用酚酞片，可能会诱发癌症！涉及多家上市公司",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "中泰国际：复星医药子公司药物获国家药监局批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "国家药监局",
                    "药物批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰国际：复星医药子公司药物获国家药监局批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-14",
            "original_text": "华创事件驱动早报1-14：工业互联网创新发展计划印发；被动元件产业链量价齐升",
            "features": {
                "keywords": [
                    "工业互联网",
                    "被动元件",
                    "量价齐升"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "制造业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华创事件驱动早报1-14：工业互联网创新发展计划印发；被动元件产业链量价齐升",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]